
radiomics.bio
radiomics.bio runs imaging analysis for cancer drug trials, turning CT, MRI and PET scans into quantitative data that biotech and pharma companies use to judge whether a treatment is working. Its Ikonics platform collects trial images and centralizes quality assessment, and the company also runs standard RECIST assessments of tumor response. The company says its radiomics and AI methods quantify treatment response and predict clinical outcomes during clinical development.
- Digital Health
- Artificial Intelligence
- Data & Analytics
- Healthcare Technology
- Software Only
Funding
Raised to date
$11.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer trials often judge whether a drug works from doctors' subjective readings of scans, which vary between readers. Pulling consistent quantitative data out of those images is hard, which makes it difficult to compare treatment arms or spot a drug's effect early.
Solution
radiomics.bio is a clinical research organization that analyzes medical images for oncology trials. It extracts quantitative features from standard-of-care CT, MRI and PET scans, a process called radiomics, and combines them with advanced statistics and AI models. The company characterizes disease at patient, organ or lesion level, evaluates response per arm, per dose and per indication, and predicts clinical outcomes from imaging and clinical data. Its Ikonics platform handles image collection and central quality assessment, and the team runs standard RECIST assessments of treatment efficacy. Work covers all stages of clinical development, from image acquisition through regulatory reporting.
Target Audience
Biotech and pharmaceutical companies running oncology clinical trials, plus the radiologists and researchers who read the images.
Features
- Characterize disease with volumetric and radiomic features at patient, organ or lesion level.
- Quantify treatment response per arm, per dose and per indication.
- Explore and validate a drug's mechanism of action through biological response.
- Predict clinical outcomes from imaging and clinical data for early trial decisions.
- Collect and store trial images under regulatory and privacy requirements.
- Run RECIST assessments of oncological images to analyze treatment efficacy.